Hay Fever

29 registered clinical trials studyying Hay Fever.

Status	Trial	Sponsor	Phase
Completed	Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Stu NCT05960266	University of Zurich	EARLY_Phase 1
Completed	Evaluating the Potential of Large Language Models for Respiratory Disease Consultations NCT06457269	North Sichuan Medical College	N/A
Completed	Audio Data Collection for Identification and Classification of Coughing NCT04326309	HealthMode Inc.	—
Completed	Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis. NCT04622917	Karolinska Institutet	Phase 4
Unknown	Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced NCT03724240	ASIT Biotech S.A.	Phase 3
Completed	Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induc NCT02560948	BioTech Tools S.A.	Phase 3
Completed	Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM NCT02156791	BioTech Tools S.A.	Phase 2
Completed	Observational Study With PASCALLERG ® in Patients With Hay Fever NCT01660737	Pascoe Pharmazeutische Praeparate GmbH	—
Completed	Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvan NCT01506375	BioTech Tools S.A.	Phase 2
Completed	Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis NCT01308021	BioTech Tools S.A.	Phase 2
Completed	Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) NCT01024608	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 3
Completed	Probiotics for Reduction Of Markers In Subjects With Allergy NCT01137357	Rijnstate Hospital	N/A
Completed	Evaluation of High Speed Laser Doppler Imaging Technology NCT02619331	Centre Hospitalier Universitaire Vaudois	N/A
Completed	Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomati NCT00574379	Faes Farma, S.A.	Phase 2
Completed	PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the NCT00574210	Faes Farma, S.A.	Phase 2
Completed	A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-4 NCT00384475	AstraZeneca	Phase 3
Completed	Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhiniti NCT00305487	AstraZeneca	Phase 3
Completed	Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old NCT00261287	AstraZeneca	Phase 3
Unknown	Safety and Efficacy Study of rEV131 in Allergic Rhinitis NCT00247520	Evolutec Group	Phase 1 / Phase 2
Completed	Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a N NCT00659503	AstraZeneca	Phase 3
Completed	Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With NCT00163488	AstraZeneca	Phase 3
Completed	Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as NCT00659594	AstraZeneca	Phase 3
Completed	To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perenn NCT00658918	AstraZeneca	Phase 3
Completed	Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinit NCT00163514	AstraZeneca	Phase 3
Completed	Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorder NCT00189917	Bavarian Nordic	Phase 1
Completed	To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allerg NCT00659841	AstraZeneca	Phase 3
Completed	Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Ye NCT00163501	AstraZeneca	Phase 3
Completed	Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies NCT00078195	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of NCT02932774	Johnson & Johnson Consumer and Personal Products Worldwide	Phase 4